Fzata, Inc. - duplicate
- Biotech or pharma, therapeutic R&D
BioPYM LBP yeast oral biologics platform. >$24 MM non-dilutive from NIH. FZ002 FIH P1 trial in 2025 for C. diff. Seeking partners for IBD, C. diff, and abdominal pain assets.
)
)
)
)
){kind=logo}
){kind=logo}
)
){kind=logo}
)
){kind=logo}